相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy via Inhibiting the Hippo/YAP, NRF2-ARE, and AKT/mTOR/ERK Pathways in A375 Melanoma Cells
Hongxia Li et al.
FRONTIERS IN ONCOLOGY (2022)
Muscle 4EBP1 activation modifies the structure and function of the neuromuscular junction in mice
Seok-Ting J. Ang et al.
NATURE COMMUNICATIONS (2022)
Mechanisms of muscle atrophy and hypertrophy: implications in health and disease
Roberta Sartori et al.
NATURE COMMUNICATIONS (2021)
Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA
Dmitry Evseev et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2021)
Molecular Mechanisms of Skeletal Muscle Hypertrophy
Stefano Schiaffino et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2021)
Displaced Myonuclei in Cancer Cachexia Suggest Altered Innervation
Nissrine Daou et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Fibrogenesis in LAMA2-Related Muscular Dystrophy Is a Central Tenet of Disease Etiology
Anthony Accorsi et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2020)
Laminin-111 protein therapy after disease onset slows muscle disease in a mouse model of laminin-alpha 2 related congenital muscular dystrophy
Pamela Barraza-Flores et al.
HUMAN MOLECULAR GENETICS (2020)
LAMA2 Neuropathies: Human Findings and Pathomechanisms From Mouse Models
Stefano Carlo Previtali et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2020)
A Family of Laminin α2 Chain-Deficient Mouse Mutants: Advancing the Research on LAMA2-CMD
Kinga I. Gawlik et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2020)
LAMA2-Related Dystrophies: Clinical Phenotypes, Disease Biomarkers, and Clinical Trial Readiness
Anna Sarkozy et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2020)
Gene therapy: a double-edged sword with great powers
Ran Tang et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2020)
JNK signaling contributes to skeletal muscle wasting and protein turnover in pancreatic cancer cachexia
Scott E. Mulder et al.
CANCER LETTERS (2020)
LAMA2-related muscular dystrophy: Natural history of a large pediatric cohort
Alberto A. Zambon et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)
Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data
Kata Czirbesz et al.
PATHOLOGY & ONCOLOGY RESEARCH (2019)
The Cutting Edge: The Role of mTOR Signaling in Laminopathies
Francesca Chiarini et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
mTORC1 underlies age-related muscle fiber damage and loss by inducing oxidative stress and catabolism
Huibin Tang et al.
AGING CELL (2019)
Role of Transforming Growth Factor- in Skeletal Muscle Fibrosis: A Review
Ahmed Ismaeel et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-α2 chain-deficient congenital muscular dystrophy
Quynh Nguyen et al.
APPLICATION OF CLINICAL GENETICS (2019)
Inhibition of the JNK/MAPK signaling pathway by myogenesis-associated miRNAs is required for skeletal muscle development
Shu-Juan Xie et al.
CELL DEATH AND DIFFERENTIATION (2018)
Canonical signaling and nuclear activity of mTORa teamwork effort to regulate metabolism and cell growth
Vincent Giguere
FEBS JOURNAL (2018)
Laminin α1 reduces muscular dystrophy in dy2J mice
Kinga Gawlik et al.
MATRIX BIOLOGY (2018)
STAT3 in Skeletal Muscle Function and Disorders
Eleonora Guadagnin et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Effects of metformin on congenital muscular dystrophy type 1A disease progression in mice: a gender impact study
Cibely C. Fontes-Oliveira et al.
SCIENTIFIC REPORTS (2018)
Impaired fetal muscle development and JAK-STAT activation mark disease onset and progression in a mouse model for merosin-deficient congenital muscular dystrophy
Andreia M. Nunes et al.
HUMAN MOLECULAR GENETICS (2017)
Correction of a splicing defect in a mouse model of congenital muscular dystrophy type 1A using a homology-directed-repair-independent mechanism
Dwi U. Kemaladewi et al.
NATURE MEDICINE (2017)
Linker proteins restore basement membrane and correct LAMA2-related muscular dystrophy in mice
Judith R. Reinhard et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Fibrosis development in early-onset muscular dystrophies: Mechanisms and translational implications
Antonio L. Serrano et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2017)
Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis
Debomita Chakraborty et al.
NATURE COMMUNICATIONS (2017)
Clinical Pharmacokinetics of Vemurafenib
Weijiang Zhang et al.
CLINICAL PHARMACOKINETICS (2017)
STAT3 promotes IFNγ/TNFα-induced muscle wasting in an NF-κB-dependent and IL-6-independent manner
Jennifer F. Ma et al.
EMBO MOLECULAR MEDICINE (2017)
IGF-1/GH axis enhances losartan treatment in Lama2-related muscular dystrophy
Anthony Accorsi et al.
HUMAN MOLECULAR GENETICS (2016)
Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy
Steven J. Foltz et al.
SKELETAL MUSCLE (2016)
Bortezomib Does Not Reduce Muscular Dystrophy in the dy2J/dy2J Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy
Zandra Korner et al.
PLOS ONE (2016)
Compromised MAPK signaling in human diseases: an update
Eun Kyung Kim et al.
ARCHIVES OF TOXICOLOGY (2015)
Prevalence of congenital muscular dystrophy in Italy A population study
Alessandra Graziano et al.
NEUROLOGY (2015)
Life or death by NFκB, Losartan promotes survival in dy2J/dy2J mouse of MDC1A
M. Elbaz et al.
CELL DEATH & DISEASE (2015)
Genotype/phenotype analysis in Chinese laminin-α2 deficient congenital muscular dystrophy patients
H. Xiong et al.
CLINICAL GENETICS (2015)
mTOR Overactivation and Compromised Autophagy in the Pathogenesis of Pulmonary Fibrosis
Yao-Song Gui et al.
PLOS ONE (2015)
Bortezomib Partially Improves Laminin α2 Chain-Deficient Muscular Dystrophy
Zandra Korner et al.
AMERICAN JOURNAL OF PATHOLOGY (2014)
Laminin-111 improves muscle repair in a mouse model of merosin-deficient congenital muscular dystrophy
Pam M. Van Ry et al.
HUMAN MOLECULAR GENETICS (2014)
Quantitative Proteomic Analysis Reveals Metabolic Alterations, Calcium Dysregulation, and Increased Expression of Extracellular Matrix Proteins in Laminin α2 Chain-deficient Muscle
Bruno Menezes de Oliveira et al.
MOLECULAR & CELLULAR PROTEOMICS (2014)
Vemurafenib in Pediatric Patients With BRAFV600E Mutated High-Grade Gliomas
Francisco Bautista et al.
PEDIATRIC BLOOD & CANCER (2014)
mTORC1 Promotes Denervation-Induced Muscle Atrophy Through a Mechanism Involving the Activation of FoxO and E3 Ubiquitin Ligases
Huibin Tang et al.
SCIENCE SIGNALING (2014)
Dysregulation of matricellular proteins is an early signature of pathology in laminin-deficient muscular dystrophy
Thomas Mehuron et al.
SKELETAL MUSCLE (2014)
Sustained Activation of mTORC1 in Skeletal Muscle Inhibits Constitutive and Starvation-Induced Autophagy and Causes a Severe, Late-Onset Myopathy
Perrine Castets et al.
CELL METABOLISM (2013)
Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice
Yoshitsugu Aoki et al.
HUMAN MOLECULAR GENETICS (2013)
Omigapil Treatment Decreases Fibrosis and Improves Respiratory Rate in dy2J Mouse Model of Congenital Muscular Dystrophy
Qing Yu et al.
PLOS ONE (2013)
Molecular basis of MAP kinase regulation
Wolfgang Peti et al.
PROTEIN SCIENCE (2013)
BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling
Harina Vin et al.
ELIFE (2013)
Inhibition of extracellular signal-regulated kinase 1/2 signaling has beneficial effects on skeletal muscle in a mouse model of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutation
Antoine Muchir et al.
SKELETAL MUSCLE (2013)
Laminin-111 Protein Therapy Reduces Muscle Pathology and Improves Viability of a Mouse Model of Merosin-Deficient Congenital Muscular Dystrophy
Jachinta E. Rooney et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Losartan, a therapeutic candidate in congenital muscular dystrophy: Studies in the dy2J/dy2J Mouse
Moran Elbaz et al.
ANNALS OF NEUROLOGY (2012)
Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma
Jason J. Luke et al.
CLINICAL CANCER RESEARCH (2012)
PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis
Simon M. Schultze et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2012)
Angiotensin II type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-alpha 2-deficient congenital muscular dystrophy (MDC1A)
Sarina Meinen et al.
SKELETAL MUSCLE (2012)
Proteasome inhibition improves the muscle of laminin α2 chain-deficient mice
Virginie Carmignac et al.
HUMAN MOLECULAR GENETICS (2011)
Autophagy is increased in laminin α2 chain-deficient muscle and its inhibition improves muscle morphology in a mouse model of MDC1A
Virginie Carmignac et al.
HUMAN MOLECULAR GENETICS (2011)
Transgenic overexpression of the α7 integrin reduces muscle pathology and improves viability in the dyW mouse model of merosin-deficient congenital muscular dystrophy type 1A
Jinger A. Doe et al.
JOURNAL OF CELL SCIENCE (2011)
Rapamycin Ameliorates Dystrophic Phenotype in mdx Mouse Skeletal Muscle
Saman Eghtesad et al.
MOLECULAR MEDICINE (2011)
The Ras Antagonist, Farnesylthiosalicylic Acid (FTS), Decreases Fibrosis and Improves Muscle Strength in dy2J/dy2J Mouse Model of Muscular Dystrophy
Yoram Nevo et al.
PLOS ONE (2011)
Skeletal muscle laminin and MDC1A: pathogenesis and treatment strategies
Kinga I. Gawlik et al.
SKELETAL MUSCLE (2011)
Consensus Statement on Standard of Care for Congenital Muscular Dystrophies
Ching H. Wang et al.
JOURNAL OF CHILD NEUROLOGY (2010)
Autophagy: cellular and molecular mechanisms
Danielle Glick et al.
JOURNAL OF PATHOLOGY (2010)
TRANSGENIC OVEREXPRESSION OF LAMININ α1 CHAIN IN LAMININ α2 CHAIN-DEFICIENT MICE RESCUES THE DISEASE THROUGHOUT THE LIFESPAN
Kinga I. Gawlik et al.
MUSCLE & NERVE (2010)
FIBROSIS INHIBITION AND MUSCLE HISTOPATHOLOGY IMPROVEMENT IN LAMININ-α2-DEFICIENT MICE
Yoram Nevo et al.
MUSCLE & NERVE (2010)
Improved muscle strength and mobility in the dy2J/dy2J mouse with merosin deficient congenital muscular dystrophy treated with Glatiramer acetate
Oshrat Dadush et al.
NEUROMUSCULAR DISORDERS (2010)
Genotype-phenotype correlation in a large population of muscular dystrophy patients with LAMA2 mutations
Fatemeh Geranmayeh et al.
NEUROMUSCULAR DISORDERS (2010)
Muscle Wasting and Impaired Myogenesis in Tumor Bearing Mice Are Prevented by ERK Inhibition
Fabio Penna et al.
PLOS ONE (2010)
Pathology Is Alleviated by Doxycycline in a Laminin-alpha 2-Null Model of Congenital Muscular Dystrophy
Mahasweta Girgenrath et al.
ANNALS OF NEUROLOGY (2009)
Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population
Fiona L. M. Norwood et al.
BRAIN (2009)
Scaffold-forming and Adhesive Contributions of Synthetic Laminin-binding Proteins to Basement Membrane Assembly
Karen K. McKee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Omigapil Ameliorates the Pathology of Muscle Dystrophy Caused by Laminin-α2 Deficiency
Michael Erb et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy
Douglas P. Millay et al.
NATURE MEDICINE (2008)
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
James A. McCubrey et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
MAP kinases and the control of nuclear events
A. G. Turjanski et al.
ONCOGENE (2007)
Bone marrow transplantation improves outcome in a mouse model of congenital muscular dystrophy
Hiroki Hagiwara et al.
FEBS LETTERS (2006)
Expression profiling of muscles from Fukuyama-type congenital muscular dystrophy and laminin-α2 deficient congenital muscular dystrophy;: is congenital muscular dystrophy a primary fibrotic disease?
M Taniguchi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Genetic background influences muscular dystrophy
A Heydemann et al.
NEUROMUSCULAR DISORDERS (2005)
Amelioration of laminin-α2-deficient congenital muscular dystrophy by somatic gene transfer of miniagrin
CP Qiao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
A simplified laminin nomenclature
M Aumailley et al.
MATRIX BIOLOGY (2005)
Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression
DC Fingar et al.
ONCOGENE (2004)
EMG and nerve conduction studies in children with congenital muscular dystrophy
S Quijano-Roy et al.
MUSCLE & NERVE (2004)
Laminin α1 chain reduces muscular dystrophy in laminin α2 chain deficient mice
K Gawlik et al.
HUMAN MOLECULAR GENETICS (2004)
The congenital muscular dystrophies in 2004: a century of exciting progress
F Muntoni et al.
NEUROMUSCULAR DISORDERS (2004)
Laminin α2 deficiency and muscular dystrophy;: genotype-phenotype correlation in mutant mice
LT Guo et al.
NEUROMUSCULAR DISORDERS (2003)
Complement 3 deficiency and oral prednisolone improve strength and prolong survival of laminin α2-deficient mice
AM Connolly et al.
JOURNAL OF NEUROIMMUNOLOGY (2002)
Merosin-deficient congenital muscular dystrophy, autosomal recessive (MDC1A, MIM#156225, LAMA2 gene coding for α2 chain of laminin)
V Allamand et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2002)
Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo
SC Bodine et al.
NATURE CELL BIOLOGY (2001)
The expanding phenotype of laminin α2 chain (merosin) abnormalities:: case series and review
KJ Jones et al.
JOURNAL OF MEDICAL GENETICS (2001)
An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy
J Moll et al.
NATURE (2001)
Schwann cell myelination occurred without basal lamina formation in laminin α2 chain-null mutant (dy3K/dy3K) mice
M Nakagawa et al.
GLIA (2001)
IGF-I treatment improves the functional properties of fast- and slow-twitch skeletal muscles from dystrophic mice
GS Lynch et al.
NEUROMUSCULAR DISORDERS (2001)
Eotaxin and eosinophil recruitment: implications for human disease
SM Rankin et al.
MOLECULAR MEDICINE TODAY (2000)
分享论文
